Eurobio Onkologie
EndoPredict®: Frequently Asked Questions
Find Clear Answers to the Questions We Hear Most
What makes EndoPredict different from other breast cancer prognostic tests?
What makes EndoPredict different is that it combines thoughtful gene selection with clinical-pathological insight. EndoPredict stands out because it is more accurate than first-generation tests and identifies a higher number of true low-risk patients compared to other second-generation tests.1,2 It can predict the risk of distant breast cancer recurrence up to 15 years after diagnosis.3
Unlike other tests, EndoPredict provides a clear, individualized estimate of the 10-year benefit from chemotherapy.4 This personalized information is valuable for both pre- and postmenopausal patients,5-7 helping guide treatment decisions today and in the future, offering patients greater confidence and peace of mind.
How accurate is EndoPredict?
Is EndoPredict a genetic test like BRCA testing?
No, EndoPredict is not the same as BRCA testing. EndoPredict is a genomic test that analyzes the activity of specific genes within your tumor to estimate how likely the cancer is to grow or spread.5 This helps you and your doctor make personalized treatment decisions. BRCA germline testing, on the other hand, is a genetic test that looks for inherited changes in the sequence of cancer realted genes (mutations) linked to a higher lifetime risk of developing breast cancer.
Are there any risks or side effects associated with the test?
No, there are no risks or side effects from the EndoPredict test itself. The test is performed using a small sample of your tumor tissue that was already removed during your biopsy or surgery – so no additional procedure is needed. EndoPredict is a laboratory test that analyzes your tumor’s genomic information to help guide treatment decisions accurately. If you have concerns about the test or the sample collection, please discuss them with your doctor.
Can EndoPredict be used when lymph nodes are involved?
Yes, EndoPredict is validated for use in patients with positive lymph nodes as well as in those with no lymph node involvement.3,8 Guidelines recommend these kind of genomic tests for patients with up to three affected lymph nodes. EndoPredict gives the most accurate prognosis for node positive patients, guiding both early and long-term treatment planning.1,2
Can EndoPredict be used in premenopausal patients?
Yes, EndoPredict is validated and recommended for use in both premenopausal and postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer.5-7 For premenopausal women, treatment decisions can be especially complex – and EndoPredict provides clear results and important guidance. The test helps determine how likely your cancer is to come back and whether you are likely to benefit from chemotherapy in addition to hormone therapy – independent of menopausal status.
Can EndoPredict be used for metastatic breast cancer?
No, EndoPredict is designed for use in early-stage breast cancer, specifically hormone receptor-positive, HER2-negative tumors.5 It helps assess the risk of distant recurrence and guides decisions about the need for chemotherapy and long-term endocrine therapy. For patients with metastatic (advanced) breast cancer, other evaluations are used to guide treatment. If you have questions about options for metastatic disease, speak with your doctor – they can help determine what’s most appropriate for your situation.
How can I get the EndoPredict test?
Your doctor can order the EndoPredict test if you have been diagnosed with hormone receptor-positive, HER2-negative early breast cancer. The test is performed on a small sample of your tumor tissue that was already removed during your biopsy or surgery – no new procedure is needed.
Here’s how it works: Your doctor orders the test, sends the tumor sample to a certified local lab and your personalized result is usually available within a few days and sent directly to your doctor. Talk to your doctor to find out if EndoPredict is right for you. We’re also happy to provide more information if needed.
Do I need to get tested more than once?
No, EndoPredict is a one-time test. It analyzes the biology of your tumor using tissue that was already removed during your biopsy or surgery.
Because it provides both short-term and long-term risk information – including the likelihood of distant recurrence up to 15 years – there’s no need to repeat the test later. The result supports treatment decisions now and helps plan for the years ahead.
When will my treatment begin?
Your treatment usually starts after your case has been discussed in a multidisciplinary tumor board, where doctors from different specialties review your diagnosis and recommend the best approach. If your doctor requests the EndoPredict test, the result is typically available within a few days and can be included in the tumor board discussion and used to finalize the treatment plan. This way, EndoPredict helps ensure your treatment is personalized to your individual situation and based on the most relevant information – even if it takes a little time to make the right decision.
Where can I find more information?
You can find more information about EndoPredict on our website or just download our patient brochure. For reliable and personalized information about breast cancer, genomic testing, and treatment options, your healthcare provider or oncologist is the best source.
In addition, trusted cancer organizations such as the American Cancer Society, BreastCancer.org, and the National Cancer Institute offer valuable resources. Patient support groups and advocacy organizations can also provide helpful guidance and connect you with others who share similar experiences.
Is EndoPredict covered by insurance?
Coverage for EndoPredict varies across countries and healthcare systems. In many European countries, the test is reimbursed through national health services or public insurance schemes, while in others private insurance may cover it. Many healthcare providers worldwide recognize the clinical value of EndoPredict in guiding breast cancer treatment decisions, and coverage is increasingly being established based on local reimbursement policies and clinical guidelines. Because coverage differs by country and individual insurance plans, it’s best to check with your healthcare provider or insurance company about whether EndoPredict is covered in your specific situation. Eurobio Oncology’s support team can also help provide guidance on coverage options available in your region.
- Still have Questions?
Take a look at our patient webpage for more detailed information about EndoPredict, or get in touch with us – we’re happy to support you.
Referenzen
- Buus R. et al.: Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
- Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
- Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
- Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
- Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011
- Constantinidou A. et al.: Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer. Clin. Cancer Res. 2022
- Klein, E. et al.: Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024
- Schmitt, W. D. et al.: Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry. SABCS 2022
- Loibl S. et al.: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
